Approval · Notice of Compliance 31447 · 2023
LIBTAYO: Notice of Compliance 31447
Issued August 15, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31447
- Date
- August 15, 2023
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfillment of commitment 2 of the Letter of Undertaking dated March 14, 2019 issued under NDS control number 218718
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LIBTAYO | Not yet assigned | — |
Medicinal ingredients
- CEMIPLIMAB 250 MG per 5ML
- CEMIPLIMAB 350 MG per 7ML